Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670981 · ClinicalTrials.gov registry record · Phase 2
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
A Phase 2 study, sponsored by Vericel Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT01670981 is a Phase 2 study that has completed, run by Vericel Corporation. The registered enrollment target is 114 participants.
The verdict
NCT01670981, a Phase 2 study, has completed, sponsored by Vericel Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study is designed to assess the efficacy, safety and tolerability of ixmyelocel-T compared to placebo (vehicle control) when administered via transendocardial catheter-based injections to patients with end stage heart failure due to IDCM, who have no reasonable revascularization options (either surgical or percutaneous interventional) likely to provide clinical benefit.
Interventions
- OTHER Placebo
- BIOLOGICAL ixmyelocel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2013-02-20 |
| Est. Completion | 2018-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670981
The ClinicalTrials.gov registry entry for NCT01670981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vericel Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01670981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01670981 about?
NCT01670981 is a clinical study titled "An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)". This study is designed to assess the efficacy, safety and tolerability of ixmyelocel-T compared to placebo (vehicle control) when administered via transendocardial catheter-based injections to patients with end stage heart failure due to IDCM, who have no reasonable revascularization options (either...
What is the current status of trial NCT01670981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2013-02-20. Estimated completion is 2018-03-07.
What interventions are being tested in trial NCT01670981?
The interventions under investigation include: Placebo (OTHER), ixmyelocel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01670981?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.